Results 11 to 20 of about 41,281 (176)

Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT The topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2‐targeted antibody–drug conjugate (ADC) trastuzumab deruxtecan (T‐DXd) is eliminated by hepatic uptake via OATP1B1/3, metabolism by CYP3A, biliary excretion via P‐glycoprotein and breast cancer resistance protein, and urinary excretion.
Watanabe A, Gill KL, Chen KF, Jones HM, De Sousa Mendes M, Gardner I, Kotsuma M.   +6 more
europepmc   +2 more sources

he impact of drug-loading factors on the solid-state form of ritonavir-mesoporous silica systems

British Journal of Pharmacy, 2022
Among the formulation techniques used to enhance the solubility and dissolution rate of poorly, aqueous-soluble drugs, mesoporous silica drug delivery systems have shown promise.
Tanweer Al-Dagamin, Joseph P O'Shea , Abina Crean   +2 more
doaj   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID-19 and Severe Renal Impairment. [PDF]

Clin Pharmacol Ther
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Gerhart J, Bramson CR, Goulding M, Shi H, Oladoyinbo O, Chan PLS, Chime S, Hammond J.   +7 more
europepmc   +2 more sources

Case Report: Multimodal Imaging of Toxic Retinopathies Related to Human Immunodeficiency Virus Antiretroviral Therapies: Maculopathy vs. Peripheral Retinopathy. Report of Two Cases and Review of the Literature

Frontiers in Neurology, 2021
Purpose: We report two patients with toxic retinopathy from either ritonavir or didanosine and reviewed the literature on the topics. We provide an overview of the retinal toxicity of these two antiretroviral drugs in human immunodeficiency virus ...
Arthur Hammer, François-Xavier Borruat
doaj   +1 more source

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

BMC Infectious Diseases, 2017
Background Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.
Tony Antoniou, Leah Szadkowski, Sharon Walmsley, Curtis Cooper, Ann N. Burchell, Ahmed M. Bayoumi, Julio S. G. Montaner, Mona Loutfy, Marina B. Klein, Nima Machouf, Christos Tsoukas, Alexander Wong, Robert S. Hogg, Janet Raboud, The Canadian Observational Cohort (CANOC) collaboration   +14 more
doaj   +1 more source

Scutellaria baicalensis decreases ritonavir-induced nausea

AIDS Research and Therapy, 2005
Background Protease inhibitors, particularly ritonavir, causes significant gastrointestinal disturbances such as nausea, even at low doses. This ritonavir-induced nausea could be related to its oxidative stress in the gut.
Chang Wei-Tien, Mehendale Sangeeta, Aung Han, Wang Chong-Zhi, Xie Jing-Tian, Yuan Chun-Su   +5 more
doaj   +1 more source

Awareness on current status of usage of ritonavir in the management of covid among dental students

Journal of Advanced Pharmaceutical Technology & Research, 2022
Ritonavir's pharmacodynamics raise questions regarding whether medication concentrations high enough to block the SARS-CoV-2 proteases can be obtained. Ritonavir may have a therapeutic benefit at any stage of the disease, although pharmacodynamic issues ...
Jagadheeswari Ramamoorthy, Dhanraj Ganapathy, Kiran Kumar Pandurangan, Nabeel Ahmed, Subhabrata Maiti   +4 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Clinical Case Reports, 2020
Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that
Hayato Koba, Taro Yoneda, Tomoya Kaneda, Tsukasa Ueda, Hideharu Kimura, Kazuo Kasahara   +5 more
doaj   +1 more source

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Frontiers in Pharmacology, 2021
Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods:
Mario Karolyi, Sara Omid, Erich Pawelka, Bernd Jilma, Thomas Stimpfl, Christian Schoergenhofer, Hermann Laferl, Tamara Seitz, Marianna Traugott, Christoph Wenisch, Alexander Zoufaly   +10 more
doaj   +1 more source